Madrigal Pharmaceuticals Wins Accelerated Approval for Rezdiffra From FDA
By Denny Jacob
Madrigal Pharmaceuticals' Rezdiffra was granted accelerated approval from the Food and Drug Administration.
The clinical-stage biopharmaceutical company noted the approval for Rezdiffra, in conjunction with diet and exercise, was to treat adults with noncirrhotic nonalcoholic steatohepatitis with moderate to advanced liver fibrosis.
Madrigal said Rezdiffra is expected to be available to patients in the U.S. in April and will be distributed through a limited specialty pharmacy network.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 14, 2024 17:05 ET (21:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst